Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06892639 · ClinicalTrials.gov registry record · Phase 3

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

A Phase 3 study of Dystrophic Epidermolysis Bullosa, sponsored by Castle Creek Biosciences.

Active
Registry status
Phase 3
Development phase
32
Enrollment target
4
Study locations

NCT06892639 is a Phase 3 study of Dystrophic Epidermolysis Bullosa that is active but no longer recruiting, run by Castle Creek Biosciences. The registered enrollment target is 32 participants, above the 16-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (100% higher). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06892639, a Phase 3 study of Dystrophic Epidermolysis Bullosa, is active but no longer recruiting, sponsored by Castle Creek Biosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
32 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Conditions Studied

Dystrophic Epidermolysis Bullosa

Interventions

  • BIOLOGICAL D-Fi

Study Locations (4)

California

  • Stanford University School of Medicine, Dermatology - Redwood City
  • Mission Dermatology - Santa Margarita

Colorado

  • Children's Hospital Colorado - Aurora

Massachusetts

  • University of Massachusetts - Worcester

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-03-27
Est. Completion 2042-02
Phase Phase 3

Sponsor

Castle Creek Biosciences

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06892639

The ClinicalTrials.gov registry entry for NCT06892639 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 16-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (100% higher). The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dystrophic Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which D-Fi is the first listed.

NCT06892639 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06892639 about?

NCT06892639 is a clinical study titled "Evaluation of D-Fi for the Treatment of Wounds Due to DEB". The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

What is the current status of trial NCT06892639?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2025-03-27. Estimated completion is 2042-02.

What conditions does trial NCT06892639 study?

This clinical trial studies the following conditions: Dystrophic Epidermolysis Bullosa.

What interventions are being tested in trial NCT06892639?

The interventions under investigation include: D-Fi (BIOLOGICAL).

Who is sponsoring clinical trial NCT06892639?

This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06892639 being conducted?

This trial has 4 study locations across California, Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dystrophic Epidermolysis Bullosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dystrophic Epidermolysis Bullosa

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.